Researchers have announced significant progress in the fight against persistent high-risk human papillomavirus (HPV) infections, a condition that can lead to cervical cancer. Daré Bioscience has received a second $1 million grant from the National Institutes of Health (NIH), bringing their total funding for the investigational treatment DARE-HPV to $2 million. This funding comes as the company initiates a Phase 2 clinical study, marking the first time women with this type of HPV infection may access a pharmacologic treatment through a clinical trial.

This development is crucial for the estimated 6 million women in the U.S. who experience high-risk HPV infections annually, as there are currently no FDA-approved medications available. The DARE-HPV treatment aims to provide a non-surgical, localized option for these women, potentially changing the current “watchful waiting” approach, where patients are monitored but receive no active treatment. If successful, DARE-HPV could become the first FDA-approved pharmacologic treatment for high-risk HPV, significantly improving women’s health outcomes and reducing the risk of cervical cancer.

The Phase 2 study will involve around 100 women and is designed to evaluate the safety and effectiveness of DARE-HPV over a 21-day treatment course. While this is a promising step forward, it is important to note that the results are still pending, with topline data expected in 2027. This research is still in the early stages, and while the funding and initial trials are encouraging, further evidence will be needed to confirm the treatment’s effectiveness and safety.

Source: globenewswire.com